StockMirror — Stock Screener

JUBLINGREA Q1 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Jubilant Ingrevia reported a strong Q1 FY27 with revenue of INR1,300 crore (25% YoY growth) and EBITDA of INR209 crore (36% YoY growth). Performance was driven by Specialty Chemicals (CDMO pipeline expansion), Nutrition (pricing and volume momentum), and Chemical Intermediates (rebound). Management remains confident of sequential improvement and maintained EBITDA guidance of INR750-800 crore for FY27. Key risks include geopolitical uncertainties, CDMO contract timing, and Nutrition pricing volatility.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasizes a balanced approach: driving volume and revenue growth via CDMO/nutrition/specialty while protecting margins through cost pass-through, lean savings, and product mix improvement. The Pinnacle strategy targets both revenue expansion and EBITDA growth.

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited (JUBLINGREA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More